Funding Resources
Funding Overview
Funding Strategy
Funding Opportunities
Grant Mechanisms
Training & Career
Development
Contracts Management
Review Committees
Funding News
Program Areas
Research
Anticonvulsant Screening
Program
Clinical Research
Counterterrorism
| Epilepsy Research Web |
NINDS is part of the
National Institutes of
Health
| Feature |
|---|
|
Videos, Slides and Photos from the Conference Now Available!
|
Epilepsy is a disorder characterized by recurring seizures, which are disturbances in the electrical activity in the brain. Seizure types range from a momentary disruption of senses to a loss of consciousness and violent movements that can last for minutes. Epilepsy affects people of all ages, from infants to the aged. There is no single cause for epilepsy; however epilepsy can sometimes be associated with a positive family history, illness, head injury, or abnormal brain development. It is estimated that 1-2% of the population has epilepsy, and of those individuals, approximately two-thirds respond well to medical treatment. NIH/NINDS and its community-based research partners are dedicated to finding a cure and/or preventing epilepsy in individuals who have or are at risk for seizures. This web page is designed to provide some information about ongoing epilepsy research efforts.
Select this link for more information about epilepsy: NINDS Epilepsy Information Page
New! NINDS publication: Curing Epilepsy: The Promise of Research
Table of Contents (click to jump to sections)
"Benchmarks" for Epilepsy Research
NINDS Anticonvulsant Screening Program
The Judith Hoyer Lecture on Epilepsy
Workshop Summaries
Workshop Publications
Recent Initiatives
Congressional Appropriations Committee Reports
Additional Links
The Anticonvulsant Screening Program (ASP) is a government sponsored effort to encourage and to facilitate the discovery of new therapeutic agents for the treatment of seizure disorders. The ASP has as its major goal the establishment of worldwide collaborative relationships among the government, academia, and industry to search for a cure of the epilepsies and to provide the necessary incentives for discovery, characterization, and development of novel antiseizure/anticonvulsant agents. These efforts are undertaken through multilevel testing directed toward the development of safer and more effective therapies for treating the various seizure disorders. The biological information generated and the consultations provided aid our participants in developing unique insights concerning the pharmacokinetic and pharmacodynamic properties of the compounds tested. ASP thus provides a strong incentive to researchers working in this and other fields. The success of these efforts directly translates into new treatments for patients afflicted with seizure disorders.
Select this link to view additional information about the NINDS ASP program
Select this link to view additional NINDS funding information by program area
Last updated June 23, 2008